/PRNewswire/ Ratio Therapeutics Inc. (Ratio), a pharmaceutical company specializing in the development of targeted radiotherapeutics for the treatment of.
Improving Survival in First-Line Metastatic NSCLC with Dual Checkpoint Blockade healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
Irinotecan liposome injection combined with 5-FU/leucovorin and oxaliplatin prolonged OS compared with nab-paclitaxel and gemcitabine as initial treatment for patients with metastatic pancreatic ductal adenocarcinoma, study results showed.The irinotecan liposome injection regimen, known as NALIRIFOX, also exhibited a manageable safety profile consistent with that of each treatment component,
Liposomal irinotecan plus chemo in the new NALIRIFOX regimen significantly improved overall survival compared with standard therapy in metastatic pancreatic ductal adenocarcinoma.
NEW ORLEANS — Odronextamab showed promising efficacy among patients with grade 1 to grade 3a follicular lymphoma who received two or more prior lines of therapy, according to study results presented at ASH Annual Meeting and Exposition.Three-quarters of patients in the cohort achieved complete remission with the hinge-stabilized, human immunoglobulin G4-based CD20 x CD3 bispecific antibody,